1. Home
  2. CFFI vs DSGN Comparison

CFFI vs DSGN Comparison

Compare CFFI & DSGN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • CFFI
  • DSGN
  • Stock Information
  • Founded
  • CFFI 1927
  • DSGN 2017
  • Country
  • CFFI United States
  • DSGN United States
  • Employees
  • CFFI N/A
  • DSGN N/A
  • Industry
  • CFFI Major Banks
  • DSGN Biotechnology: Pharmaceutical Preparations
  • Sector
  • CFFI Finance
  • DSGN Health Care
  • Exchange
  • CFFI Nasdaq
  • DSGN Nasdaq
  • Market Cap
  • CFFI 218.0M
  • DSGN 208.9M
  • IPO Year
  • CFFI 1998
  • DSGN 2021
  • Fundamental
  • Price
  • CFFI $71.30
  • DSGN $6.45
  • Analyst Decision
  • CFFI
  • DSGN
  • Analyst Count
  • CFFI 0
  • DSGN 0
  • Target Price
  • CFFI N/A
  • DSGN N/A
  • AVG Volume (30 Days)
  • CFFI 10.8K
  • DSGN 184.3K
  • Earning Date
  • CFFI 10-28-2025
  • DSGN 11-06-2025
  • Dividend Yield
  • CFFI 2.58%
  • DSGN N/A
  • EPS Growth
  • CFFI 32.15
  • DSGN N/A
  • EPS
  • CFFI 7.56
  • DSGN N/A
  • Revenue
  • CFFI $122,075,000.00
  • DSGN N/A
  • Revenue This Year
  • CFFI N/A
  • DSGN N/A
  • Revenue Next Year
  • CFFI N/A
  • DSGN N/A
  • P/E Ratio
  • CFFI $9.43
  • DSGN N/A
  • Revenue Growth
  • CFFI 7.42
  • DSGN N/A
  • 52 Week Low
  • CFFI $53.14
  • DSGN $2.60
  • 52 Week High
  • CFFI $89.90
  • DSGN $7.77
  • Technical
  • Relative Strength Index (RSI)
  • CFFI 59.21
  • DSGN 73.57
  • Support Level
  • CFFI $69.47
  • DSGN $4.92
  • Resistance Level
  • CFFI $71.98
  • DSGN $5.68
  • Average True Range (ATR)
  • CFFI 1.89
  • DSGN 0.42
  • MACD
  • CFFI 0.10
  • DSGN 0.08
  • Stochastic Oscillator
  • CFFI 72.09
  • DSGN 93.90

About CFFI C&F Financial Corporation

C&F Financial Corp is an American bank holding company. The company through its subsidiaries offers banking and related financial services to both individuals and businesses. It operates in three business activities: Community Banking, Mortgage Banking, and Consumer Finance. It mainly provides a range of lending activities, which include residential mortgage loans, commercial real estate loans, non-prime automobile lending, land acquisition, and development loans, and consumer loans. The company generates maximum of its revenue from the Community Banking segment.

About DSGN Design Therapeutics Inc.

Design Therapeutics Inc is a clinical-stage biopharmaceutical company engaged in the research and development of GeneTACTM molecules, which are a novel class of small-molecule gene-targeted chimera therapeutic candidates designed to be disease-modifying by addressing the underlying cause of diseases caused by inherited nucleotide repeat expansion mutations. The Company's product candidate is in Friedreich ataxia (FA), its second product candidate is in Fuchs endothelial corneal dystrophy (FECD), and it is also advancing its GeneTACTM program to address other serious nucleotide repeat-driven monogenic diseases.

Share on Social Networks: